Dr. Kulisevsky, director of the Movement Disorders Unit of the Sant Pau Hospital Neurology Service and head of the Parkinson’s Disease and Movement Disorders Research Group at the Sant Pau Research Institute, is the principal investigator and international coordinator of a controlled phase 2 drug study that, for the first time in 20 years, is achieving positive results for cognitive complications in Parkinson’s disease. Sant Pau Hospital has also participated as a patient recruitment centre for the study.

Annex

Subscribe to Directory
Write an Article

Recent News

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Horizon pone en marcha una planta punter...

by Horizon Products

Horizon ha puesto en funcionamiento una nueva planta dedicada íntegra...

Photos Stream